<DOC>
	<DOCNO>NCT01232296</DOCNO>
	<brief_summary>The purpose open-label , randomize , phase II study compare safety efficacy dovitinib versus sorafenib first-line treatment adult patient advance Hepatocellular Carcinoma ( HCC ) . This trial open country Asia-Pacific region .</brief_summary>
	<brief_title>A Study Dovitinib Versus Sorafenib Adult Patients With Hepatocellular Carcinoma ( HCC ) First Line Treatment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Diagnosis advance Hepatocellular Carcinoma ( HCC ) accord AASLD Guidelines Advance HCC Stage B C accord BCLC stag classification Child Pugh A At least one measurable lesion assess CT MRI ECOG PS 0 1 Adequate bone marrow , liver , renal function Prior systemic therapy HCC Brain metastasis Active bleeding ( include variceal bleed result esophageal varix ) Patients receive liver transplant await immediate transplant Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>HCC</keyword>
	<keyword>Liver cancer</keyword>
	<keyword>Child Pugh A</keyword>
	<keyword>HCC Stage C</keyword>
</DOC>